The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 1: 19 - 24

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.01.004

Feature Reports：Lung cancer

The mechanism of lipid metabolism disorders promoting progression of lung cancer based on the oxLDL/LOX⁃1 signaling pathway

  • Yang WU ,
  • Jian YAO ,
  • Jinliang. CHEN
Expand
  • *.Department of Infectious Diseases，Nantong First People's Hospital，Nantong 226001，China

Received date: 2023-07-15

  Online published: 2024-01-24

Fold

Abstract

Objective To explore the mechanism of lipid metabolism disorder promoting the progress of lung cancer based on the oxidized low density lipoprotein （ox?LDL）/ human lectin?like oxidized low density lipoprotein receptor 1（LOX?1） signaling pathway. Methods Eighty?one identified lung adenocarcinoma tissues with paired adjacent non?cancerous tissues （at least 5 cm away from the tumor） were collected from our hospital， and the expression of LOX?1 was detected by immunohistochemistry. LOX?1 was overexpressed in lung adenocarcinoma cell lines （A549 and H1299 cells）. Cell invasion ability was measured by Transwell. Cells were treated with different concentrations of oxLDL， and cellular LOX?1 expression was investigated. Results LOX?1 staining in the tumor was significantly stronger than that in the non?cancerous tissue samples （99.4 vs. 16.2 for median H score， P < 0.001）. High LOX?1 expression was significantly correlated with low survival （P < 0.001）. As compared with the patients without lymph node metastasis， those with lymph node metastasis had higher LOX?1 level （83.2 vs. 121.1 for median H score， P < 0.01）. Overexpression of LOX?1 in lung cancer cells significantly promoted the number of invasive and metastatic cells （P < 0.01）. In addition， LOX?1 was an essential functional target for oxLDL?induced metastasis of lung cancer cells. Itatinib inhibited the metastasis of LOX?1 overexpressed A549 in vitro. Conclusions With an increase in oxLDL level， the expression of LOX?1 increases. Up?regulation of LOX?1 promotes metastasis of lung cancer， and its mechanism may be related to activation of the JAK1/STAT6 signaling pathway.

Key words： oxidized low density lipoprotein; human lectin?like oxidized low density lipoprotein receptor 1; lung cancer; lipid metabolism

Cite this article

Yang WU , Jian YAO , Jinliang. CHEN . The mechanism of lipid metabolism disorders promoting progression of lung cancer based on the oxLDL/LOX⁃1 signaling pathway[J]. The Journal of Practical Medicine, 2024 , 40(1) : 19 -24 . DOI: 10.3969/j.issn.1006-5725.2024.01.004

References

1 SHUVALOV O， DAKS A， FEDOROVA O， et al. Linking metabolic reprogramming， plasticity and tumor progression［J］. Cancers， 2021， 13（4）： 762.
2 NAVARRO C， ORTEGA á， SANTELIZ R， et al. Metabolic reprogramming in cancer cells： emerging molecular mechanisms and novel therapeutic approaches［J］. Pharmaceutics， 2022， 14（6）： 1303.
3 PATEL K K， KASHFI K. Lipoproteins and cancer： The role of HDL-C， LDL-C， and cholesterol-lowering drugs［J］. Biochem Pharmacol， 2022， 196： 114654.
4 TAKAHASHI K， AONO J， NAKAO Y， et al. LOX-1 deficiency increases ruptured abdominal aortic aneurysm via thinning of adventitial collagen［J］. Hypertens Res， 2023， 46（1）： 63-74.
5 STEIN R， FERRARI F， MARTINS V M. Blood lipids and molecular pathways of atherogenesis［J］. Cholesterol， 2022： 623-637.
6 CHAI E Q， ZHANG L， LI C. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression［J］. Cancer Manag Res， 2019， 11： 7307-7315.
7 HAO F， CHEN J， WU J， et al. Expression of Serum sLOX-1 in Patients with Non-Small-Cell Lung Cancer and Its Correlation with Lipid Metabolism［J］. Can Respir J， 2022， 6619331.
8 NAKASHIMA-NAKASUGA C， HAZAMA S， SUZUKI N， et al. Serum LOX-1 is a novel prognostic biomarker of colorectal cancer［J］. Int J Clin Oncol， 2020， 25（7）： 1308-1317.
9 MURDOCCA M， DE MASI C， PUCCI S， et al. LOX-1 and cancer： an indissoluble liaison［J］. Cancer Gene Ther， 2021， 28（10/11）： 1088-1098.
10 TIAN Y， LI H， GAO Y， et al. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis［J］. Clin Proteomics， 2019， 16（1）： 6.
11 COVINGTON M， HE X， SCURON M， et al. Preclinical characterization of itacitinib （INCB039110）， a novel selective inhibitor of JAK1， for the treatment of inflammatory diseases［J］. Eur J Pharmacol， 2020， 885： 173505.
12 何婷婷， 张旭琳， 贾珍丽， 等. 硫化氢通过下调NLRP3/caspase-1信号通路抑制氧化型低密度脂蛋白诱导的血管内皮细胞焦亡［J］. 中国病理生理杂志， 2021， 37（10）： 1738-1746.
13 HUARTE E， O'CONNOR R S， PEEL M T， et al. Itacitinib （INCB039110）， a JAK1 Inhibitor， Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell TherapyItacitinib （JAK1 Inhibitor） Prevents CAR T Cell–induced CRS［J］. Clin Cancer Res， 2020， 26（23）： 6299-6309.
14 NAING A， POWDERLY J D， NEMUNAITIS J J， et al. Exploring the safety， effect on the tumor microenvironment， and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors： A phase I study［J］. J Immunother Cancer， 2022， 10（3）： e004223.
15 GONZáLEZ-CHAVARRíA I， FERNANDEZ E， GUTIERREZ N， et al. LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells［J］. Cancer Lett， 2018， 414： 34-43.
16 WANG D， CHENG X， LI Y， et al. C/EBPδ-Slug-Lox1 axis promotes metastasis of lung adenocarcinoma via oxLDL uptake［J］. Oncogene， 2020， 39（4）： 833-848.
17 TIAN X， WANG T， ZHENG Q， et al. Circulating CD15+LOX-1+ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small-cell lung cancer［J］. Int J Clin Pract， 2021， 75（8）： e14317.
18 TSUMITA T， MAISHI N， ANNAN D A M， et al. The oxidized-LDL/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells［J］. Int J Cancer， 2022， 151（6）： 944-956.
19 HE Y， GAO Y， ZHANG Q， et al. IL-4 switches microglia/macrophage M1/M2 polarization and alleviates neurological damage by modulating the JAK1/STAT6 pathway following ICH［J］. Neuroscience， 2020， 437： 161-171.
20 LI D， LU L， KONG W， et al. C-type lectin receptor Dectin3 deficiency balances the accumulation and function of FoxO1-mediated LOX-1+ M-MDSCs in relieving lupus-like symptoms［J］. Cell Death Dis， 2021， 12（9）： 829.
21 LI L， YOU W， WANG X， et al. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression［J］. Phytomedicine， 2023， 108： 154508.
22 李晨， 李晓媚， 刘亭， 等. 高盐饮食激活肠JAK1/STAT3通路诱导肠上皮屏障功能障碍［J］. 实用医学杂志， 2021， 37（1）： 35-40.
Options
Outlines

/

〈 〉